Status:
COMPLETED
Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal
Lead Sponsor:
University of Miami
Collaborating Sponsors:
Graceway Pharmaceuticals, LLC
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the efficacy of tattoo removal using topical imiquimod, 5% cream in conjunction with the 1064nm Nd:YAG laser. This procedure for tattoo removal will be compare...
Detailed Description
Inclusion criteria includes: patients of both genders with Fitzpatrick skin types I-IV who are 18-65 years of age and who has 2 tattoos from 2 to 10 cm in diameter, of similar age which contains black...
Eligibility Criteria
Inclusion
- 2 tattoos no larger than 25cm2, professionally made, with approximately the same age, containing blue/black ink.
Exclusion
- Hypersensitivity to imiquimod
- Current sun tan
- Use of vitamin E, non-steroid anti-inflammatory drugs, coumadin or aspirin for the past 10 days
- Amateur tattoos
- Pregnancy
- Breast-feeding status
- Immunosuppression
- Auto-immune diseases.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00638651
Start Date
February 1 2008
End Date
August 1 2014
Last Update
March 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohs, Dermatologic and Laser Surgery
Miami, Florida, United States, 33136